Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6249MR)

This product GTTS-WQ6249MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6249MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7237MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ10334MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ620MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ11482MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ9195MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ10289MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ9129MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ5766MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW